Search

Bio-Techne Corp

Geschlossen

BrancheGesundheitswesen

72.02 0.45

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

71.51

Max

71.83

Schlüsselkennzahlen

By Trading Economics

Einkommen

13M

51M

Verkäufe

16M

311M

KGV

Branchendurchschnitt

103.826

62.58

EPS

0.53

Dividendenrendite

0.44

Gewinnspanne

16.392

Angestellte

3,100

EBITDA

21M

99M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-6.34% downside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

0.44%

2.19%

Nächstes Ergebnis

5. Aug. 2026

Nächste Dividendenausschüttung

28. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.6B

11B

Vorheriger Eröffnungskurs

71.57

Vorheriger Schlusskurs

72.02

Nachrichtenstimmung

By Acuity

65%

35%

296 / 340 Ranking in Healthcare

Bio-Techne Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Juli 2026, 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Peer-Vergleich

Kursveränderung

Bio-Techne Corp Prognose

Kursziel

By TipRanks

-6.34% Nachteil

12-Monats-Prognose

Durchschnitt 67.09 USD  -6.34%

Hoch 73 USD

Tief 50 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bio-Techne Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

14 ratings

1

Buy

13

Halten

0

Sell

Stimmung

By Acuity

296 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat